kw 2189 has been researched along with du 86 in 2 studies
Studies (kw 2189) | Trials (kw 2189) | Recent Studies (post-2010) (kw 2189) | Studies (du 86) | Trials (du 86) | Recent Studies (post-2010) (du 86) |
---|---|---|---|---|---|
10 | 4 | 0 | 10 | 0 | 0 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (100.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ebisu, H; Fukuda, Y; Furuta, H; Kusama, Y; Oomori, Y; Terashima, S | 1 |
Funayama, Y; Isogai, Y; Kanzawa, F; Kuraishi, Y; Lee, YS; Nishio, K; Ogasawara, H; Ohira, T; Saijo, N | 1 |
2 other study(ies) available for kw 2189 and du 86
Article | Year |
---|---|
Novel cyclopropapyrroloindole derivative (AT-3510) bearing methoxycarbonyl and trifluoromethyl groups.
Topics: Animals; Antineoplastic Agents; Benzofurans; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Inbred BALB C; Prodrugs; Pyrroles; Stereoisomerism; Structure-Activity Relationship; Transplantation, Heterologous; Tumor Cells, Cultured | 1999 |
Intracellular carboxyl esterase activity is a determinant of cellular sensitivity to the antineoplastic agent KW-2189 in cell lines resistant to cisplatin and CPT-11.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Camptothecin; Carboxylic Ester Hydrolases; Carcinoma, Non-Small-Cell Lung; Carcinoma, Small Cell; Cisplatin; DNA; Drug Resistance; Drug Resistance, Multiple; Duocarmycins; Female; Humans; Irinotecan; Lung Neoplasms; Microsomes; Ovarian Neoplasms; Pyrrolidinones; Tumor Cells, Cultured | 1995 |